These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 28106706

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A.
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial.
    Lavine JA, Srivastava SK, Dukles N, Reese JL, Ehlers JP.
    Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879
    [Abstract] [Full Text] [Related]

  • 8. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K, Peter-Reichart S, Mennel S.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting.
    Wertheimer C, Haritoglou C, Laubichler P, Wolf A, Kaessmann K, Schumann RG, Priglinger S, Mayer WJ.
    Ophthalmologica; 2018 Oct; 239(1):11-18. PubMed ID: 28954271
    [Abstract] [Full Text] [Related]

  • 17. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
    Chatziralli I, Theodossiadis G, Xanthopoulou P, Miligkos M, Sivaprasad S, Theodossiadis P.
    Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1247-56. PubMed ID: 27137631
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.